Please assess the completion status of the following clinical trial:

Trial Title: A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with obesity disease and inadequately controlled body weight with diet and/or exercise~* BMI ≥ 25 kg/m\^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35 kg/m\^2 at least one obesity-related comorbidity~* Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%~* Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female~* Visceral fat area ≥ 100 cm\^2~* Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study~Exclusion Criteria:~* Pregnancy or lactating women~* Use of pharmacologically active weight-loss medications~* Bariatric surgery~* Ketoacidosis, lactic acidosis, hyperosmolar coma~* Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to screening~* Gastro-intestinal (GI) disorders associated with chronic diarrhea~* Congestive heart failure, New York Heart Association (NYHA) class III or IV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LIK066 2.5 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
- LIK066 10 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
- LIK066 25 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
- LIK066 50 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).